

Fiscal 2013 Financial Results

May 9, 2014 Isao Teshirogi, Ph.D. President & CEO





Overview of FY2013 Financial Results





(Units: B yen)

	FY2013	FY2013	achieve-	variance	FY2012	Y on Y	
	forecasts*	results	ment(%)		results	change(%)	change
Sales	284.8	289.7	101.7	4.9	282.9	2.4	6.8
Operating income	62.0	63.6	102.5	1.6	59.6	6.7	4.0
Ordinary income	61.0	63.9	104.8	2.9	58.9	8.5	5.0
Net income	43.0	41.8	97.3	(1.2)	66.7	(37.3)	(24.9)


 Operating income and ordinary income in FY2013 are higher than the levels achieved in the full year of any prior fiscal year

Note: All numerical values are rounded to the nearest unit The litigation expenses have been recognized under non-operating expenses since FY2013. We have restated the consolidated statements of income for the previous fiscal year to reflect this change (Units: Yen)

Exchange rate (average)	FY2013 forecasts	FY2013 results	FY2012 results	Y on Y
USD(\$)	95	100.18	82.95	+17.23 yen depreciation
EUR(€)	120	134.23	106.83	+27.40 yen depreciation



FY2013 Results Financial Position and Cash Flow (Consolidated)





S-O-N-G

for you!

FY2013 Results Statements of Income (Consolidated)



(Units: B yen)


FY2013 FY2012 Y on Y achievevariance ment(%) results change(%) forecasts results change 168.4 168.3 165.7 Prescription drugs 99.9 1.5 2.6 (0.1)66.4 Total of 3 key products 66.3 99.9 (0.1) 58.5 13.4 7.8 92.9 92.9 84.2 Total of 8 strategic products 100.0 (0.0)10.3 8.7 * 30.6 33.1 34.0 102.8 11.1 3.4 **Overseas subsidiaries/export** 0.9 20.7 21.4 17.0 103.3 26.0 4.4 Shionogi Inc. 0.7 Osphena[™] 5.5 1.1 20.0 (4.4)1.1 6.0 5.9 5.8 **C&O** 97.9 (0.1) 1.0 0.1 8.7 7.3 Contract manufacturing 8.4 96.3 (0.3)15.5 1.1 4.7 4.5 5.2 OTC and quasi-drugs 96.1 (0.2)(12.6)(0.7)1.9 2.0 2.2 105.7 Diagnostics 0.1 (9.0) (0.2)66.0 70.7 69.8 **Royalty income** 107.1 4.7 1.2 0.9 Crestor® 63.0 104.2 2.7 4.3 65.7 63.0 2.7 2.0 2.1 Others 1.8 90.2 (0.2)(12.7)(0.3)284.8 282.9 Total 289.7 101.7 4.9 2.4 6.8

Eight strategic products: Crestor[®], Irbetan[®] franchise, Cymbalta[®] (3 key products), and OxyContin[®] franchise, Finibax[®], Differin[®], Pirespa[®], Rapiacta[®]



* Taiwan Shionogi has changed its accounting period since Jan. 2012, and FY2012 results include 15 months from Jan. 2012 to Mar. 2013

Japan: Sales of 8 Strategic Products





FY2013 Results

FY2013 Results

Statements of Income (Consolidated)



	FY2013		achieve-	achieve- ment(%) variance		Y on Y	
	forecasts	results	ment(%)	variance	results	change(%)	change
Sales	284.8	289.7	101.7	4.9	282.9	2.4	6.8
[Royalty income]	66.0	70.7	107.1	4.7	69.8	1.2	0.9
Cost of sales	^{27.3} (35.6) 77.8	^{26.9} (35.6) 78.0	100.2	0.2	^{27.8} (36.9) 78.6	(0.7)	(0.6)
Gross profit	207.0	211.7	102.3	4.7	204.3	3.6	7.4
SG&A expenses	^{50.9} 145.0	^{51.1} 148.2	102.2	3.2	^{51.2} 144.8	2.4	3.4
Selling & general expenses	92.0	96.2	104.6	4.2	91.7	4.9	4.5
R&D expenses	53.0	51.9	98.0	(1.1)	53.0	(2.1)	(1.1)
Operating income	^{21.8} 62.0	^{21.9} 63.6	102.5	1.6	^{21.1} 59.6	6.7	4.0
[Excluding royalty income]	(4.0)	(7.1)	-	(3.1)	(10.3)	-	3.2
Non-operating income and expenses	L1.0	P0.4	-	1.4	L0.6	-	1.0
Ordinary income	^{21.4} 61.0	^{22.1} 63.9	104.8	2.9	^{20.8} 58.9	8.5	5.0
Extraordinary income and loss	P4.3	P1.0	22.4	(3.3)	L0.6	-	1.6
Income before income taxes and minority interests	65.3	64.9	99.3	(0.4)	58.3	11.3	6.6
Total income taxes, etc.	22.3	23.0	-	0.7	(8.4)	-	31.4
Net income	43.0	41.8	97.3	(1.2)	66.7	(37.3)	(24.9)



Note: Small numbers in red are percent of sales, and numbers in red provided in parentheses are percent of sales excluding royalties

FY2013 Results Changes of Our Business Operations in 1H FY2013



Started FY2013 with operating income forecast of 60 B yen at minimum

- Activities in 1H to improve the focus and constitution of our business operations to overcome Crestor cliff
 - Review and optimize fixed costs in all group companies, while investing in Osphena's launch
 - Improve behavior and profitability of Japanese domestic business
 - Accelerate reduction in cost of sales mainly through the newly established Global SCM Division

1H FY2013: All income levels for 1H were higher than the levels achieved in the 1H of any prior fiscal year (Operating income: +4.5 B yen vs. target)

- Maintain cost control in all group companies, mainly in Japan
 - SG&A and cost of sales decreased by 2.0 B yen and 1.8 B yen compared to the original forecasts
- Royalty income exceeded the original forecast by 2.4 B yen



FY2013 Results Significant Changes in the Business Environment in 2H FY2013

Significant changes in the business environment

Finalized agreement to revise Crestor royalty structure

Leveling Crestor cliff to **Crestor hill in FY2014**

Received one-time income from settlement of arbitration

Smooth launch of dolutegravir

Moving into accelerated growth phase from FY2014 onward



Changes of Our Business Operation in 2H FY2013



2H FY2013: Additional actions


- Implemented activities to ensure growth from FY2014 onward by improving our business operations and utilize the additional operating profit (+4.5 B yen compare to the original 1H forecasts)
 - Accelerated investment in key marketing activities for future growth in Japan (selling & general expenses: +4.2 B yen)
 - Japanese domestic sales: +3.0 B yen (direct to consumer education: +1.2 B yen)
 - Doripenem related costs: +0.5 B yen
 - Fluctuations in foreign exchange rates: +0.7 B yen
 - Global SCM Division streamlined inventories: -2.0 B yen in Japan (with temporary increase in cost of sales)



FY2013:

Operating income: 63.6 B yen (record, +3.6 B yen vs. original forecasts) Ordinary income: 63.9 B yen (record, +4.9 B yen vs. original forecasts)





S-O-N-C

Extraordinary income and loss: P1.0 (1H: P4.3, 2H: L3.3)

Extraordinary income: P4.8

- Gain on sales of investment securities: P0.6
- Gain on sales of noncurrent assets: P4.2 --- sales of rental properties, etc.

Extraordinary loss: L3.8

- Impairment loss: L0.9 --- property, plant and equipment
- Business structure improvement expenses: L0.8 --- due to divestiture of Naprelan[®]
- Loss on sales of noncurrent assets: L0.5
- Loss on valuation of inventories: L0.5, etc.

Actions taken to strengthen the balance sheet





FY2014 Financial Forecasts



FY2014 Forecasts Financial Forecasts (Consolidated)



(Units: B yen)

	FY2014 f	orecasts	FY2013	Y on Y		
	full year	1H	results	change(%)	change	
Sales	269.0	130.0	289.7	(7.2)	(20.7)	
Operating income	45.0	18.5	63.6	(29.2)	(18.6)	
Ordinary income	50.0	24.0	63.9	(21.8)	(13.9)	
Net income	33.0	16.0	41.8	(21.1)	(8.8)	

Note: All numerical values are rounded to the nearest unit


		(Units: Yen)
Exchange rate (average)	FY2014 forecasts	FY2013 results
USD(\$)	100	100.18
EUR(€)	140	134.23



FY2014 Forecasts Statements of Income (Consolidated)



	FY2014 forecasts		FY2013	Y on Y	
	full year	1H	results	change(%)	change
Prescription drugs	167.0	80.5	168.3	(0.8)	(1.3)
Total of 3 key products	72.0	34.5	66.3	8.5	5.7
Total of 8 strategic products	100.0	47.3	92.9	7.6	7.1
Overseas subsidiaries/export	31.3	15.0	34.0	(8.0)	(2.7)
Shionogi Inc.	17.7	7.9	21.4	(17.2)	(3.7)
Osphena	7.0	2.5	1.1	536.6	5.9
C&O	7.5	3.4	5.9	27.7	1.6
Contract manufacturing	11.4	4.8	8.4	36.1	3.0
OTC and quasi-drugs	4.6	2.4	4.5	1.9	0.1
Royalty income	52.0	26.0	70.7	(26.4)	(18.7)
Crestor	47.5	24.2	65.7	(27.7)	(18.2)
Others	2.7	1.3	3.8	(29.2)	(1.1)
Total	269.0	130.0	289.7	(7.2)	(20.7)






Sales of diagnostics have been included in Others since FY2014. We have restated the consolidated statements of income for the prior fiscal year to reflect this change

FY2014 Forecasts

Japan: Sales of 8 Strategic Products







FY2014 Forecasts Statements of Income (Consolidated)



(Units: B yen)

	FY2014 forecasts		FY201	3	Y on Y			
	full ye	ar		1H	result	S	change(%)	change
Sales		269.0		130.0	2	89.7	(7.2)	(20.7)
[Royalty income]		52.0		26.0		70.7	(26.4)	(18.7)
	29.4 (36.4)		29.2 (36.5)		26.9 (35.6)			
Cost of sales		79.0		38.0		78.0	1.3	1.0
Gross profit		190.0		92.0		211.7	(10.3)	(21.7)
	53.9		56.5		51.1			
SG&A expenses		145.0		73.5	,	148.2	(2.1)	(3.2)
Selling & general expenses		93.0		46.5		96.2	(3.4)	(3.2)
R&D expenses		52.0		27.0		51.9	0.1	0.1
· · · · · · · · · · · · · · · · · · ·	16.7		14.2		21.9			
Operating income		45.0		18.5		63.6	(29.2)	(18.6)
[Excluding royalty income]		(7.0)		(7.5)		(7.1)	-	0.1
Non-operating income and expenses		P5.0		P5.5		P0.4	-	4.6
Ordinary income	18.6	50.0	18.5	24.0	22.1	63.9	(21.8)	(13.9)



Note: Small numbers in red are percent of sales, and numbers in red provided in parentheses are percent of sales excluding royalties

FY2014 Activities Determination to Achieve New Medium-Term Business Plan "SGS2020"




Grow as a drug discovery-based pharmaceutical company

Targets for FY2020 Sales: 500 B yen Ordinary income: 125 B yen R&D expenses: 100 B yen ROE: 15%

FY2014 business plan for achieving SGS2020 target

- Leveling Crestor cliff and avoid sharp decline in corporate performance
- FY2014 is very important to prove Shionogi group's preparations and transformation
- Visualize our activities for future growth while achieving our numerical targets for FY2014

(Units: B yen)





FY2013 and FY2014 Dividend Forecasts



	Dividends per Share						
	half-year	year-end	annual				
FY2012	Yen 20.00	Yen 22.00	Yen 42.00				
FY2013	22.00	(forecast) 24.00	(forecast) 46.00				
FY2014	(forecast) 24.00	(forecast) 24.00	(forecast) 48.00				

Dividend policy

- The dividend policy was revised from payout ratio (target: 40%) to dividend on equity (DOE) at the end of FY2013
- Sharing the growth with our shareholders with further pay back as necessary
- Dividend forecast for FY2013: 46 yen (raise year-end forecast: 22 to 24 yen)
- Dividend forecast for FY2014: 48 yen



Forward-Looking Statements

- S-O-N-G for you!
- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (*kessan tanshin*) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called "forward-looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency's examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall
 accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or
 any other use of this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

